Siren L.L.C. Boosts Stock Position in Olema Pharmaceuticals, Inc. $OLMA

Siren L.L.C. lifted its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 44.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,756,949 shares of the company’s stock after buying an additional 1,456,249 shares during the quarter. Olema Pharmaceuticals makes up approximately 2.0% of Siren L.L.C.’s investment portfolio, making the stock its 12th largest position. Siren L.L.C. owned approximately 0.05% of Olema Pharmaceuticals worth $70,926,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in OLMA. AQR Capital Management LLC acquired a new stake in Olema Pharmaceuticals in the 1st quarter valued at $172,000. Goldman Sachs Group Inc. raised its position in Olema Pharmaceuticals by 93.6% during the first quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock worth $2,787,000 after acquiring an additional 358,412 shares during the period. Jane Street Group LLC raised its position in Olema Pharmaceuticals by 216.8% during the first quarter. Jane Street Group LLC now owns 138,552 shares of the company’s stock worth $521,000 after acquiring an additional 94,815 shares during the period. Geode Capital Management LLC raised its position in Olema Pharmaceuticals by 22.4% during the second quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after acquiring an additional 242,997 shares during the period. Finally, Creative Planning purchased a new position in Olema Pharmaceuticals during the second quarter valued at $83,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Guggenheim dropped their target price on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. HC Wainwright restated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Wolfe Research initiated coverage on shares of Olema Pharmaceuticals in a research note on Friday, March 27th. They issued a “peer perform” rating on the stock. Wall Street Zen upgraded Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Friday, July 17th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $44.10.

Olema Pharmaceuticals Stock Up 2.2%

NASDAQ OLMA opened at $11.74 on Friday. The business has a fifty day moving average price of $11.65 and a 200 day moving average price of $17.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. The company has a market cap of $1.03 billion, a P/E ratio of -5.81 and a beta of 2.00. Olema Pharmaceuticals, Inc. has a one year low of $4.47 and a one year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). Research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.